The titration process is designed to balance therapeutic effectiveness with tolerability
Oral bioavailability is significantly lower than injection, requiring much higher doses to achieve comparable GH release
For others, it can take longer, especially if symptoms have been present for months or if there are multiple contributing factors (iron, vitamin D, thyroid issues, sleep, stress, etc.)
SGLT2 inhibitors are preferred in people with HF or at high-risk for HF, whereas GLP-1 receptor agonists are favored for those requiring significant weight loss, ASCVD risk reduction, CKD management, or in whom mitigation of metabolic dysfunction-associated steatotic liver disease (MASLD) or steatohepatitis is a clinical priority [84]